Volume 18, Issue 8, Pages (August 2017)

Slides:

Advertisements

Similar presentations

Volume 17, Issue 11, Pages (November 2016)

Advertisements

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 2, Pages (February 2015)

Volume 376, Issue 9747, Pages (October 2010)

Volume 15, Issue 1, Pages (January 2014)

Volume 16, Issue 9, Pages (September 2015)

Volume 388, Issue 10058, Pages (November 2016)

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Volume 14, Issue 4, Pages (April 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 389, Issue 10076, Pages (April 2017)

Volume 366, Issue 9482, Pages (July 2005)

Volume 12, Issue 8, Pages (August 2011)

Volume 392, Issue 10145, Pages (August 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 389, Issue 10071, Pages (February 2017)

Volume 15, Issue 1, Pages (January 2014)

Volume 373, Issue 9663, Pages (February 2009)

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 14, Issue 7, Pages (June 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 17, Issue 9, Pages (September 2016)

Volume 392, Issue 10141, Pages (July 2018)

Volume 15, Issue 6, Pages (May 2014)

Volume 4, Issue 6, Pages (June 2017)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial Marianna Christodoulou,

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 371, Issue 9625, Pages (May 2008)

Volume 373, Issue 9676, Pages (May 2009)

Volume 388, Issue 10058, Pages (November 2016)

Volume 393, Issue 10172, Pages (February 2019)

Volume 376, Issue 9757, Pages (December 2010)

Volume 16, Issue 15, Pages (November 2015)

Volume 388, Issue 10055, Pages (October 2016)

Volume 392, Issue 10162, Pages (December 2018)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 392, Issue 10156, Pages (October 2018)

Volume 16, Issue 15, Pages (November 2015)

Volume 17, Issue 8, Pages (August 2016)

Thank you to our diverse (but not diverse enough) reviewers

Volume 11, Issue 1, Pages (January 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Effect of a behaviour change intervention on the quality of peri-urban sanitation in Lusaka, Zambia: a randomised controlled trial James B Tidwell, PhD,

Volume 5, Issue 1, Pages (January 2018)

Integrating an early childhood development programme into Bangladeshi primary health-care services: an open-label, cluster-randomised controlled trial

Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.

18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial Prakash Manoharan, MB ChB, Ahmed Salem, PhD, Hitesh Mistry, PhD,

Long-term outcomes of childhood sexual abuse: an umbrella review

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Volume 20, Issue 7, Pages (July 2019)

Sickle cell disease: a new era

Presentation transcript:

Volume 18, Issue 8, Pages 1116-1125 (August 2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited- stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial Prof Corinne Faivre-Finn, PhD, Michael Snee, DM, Linda Ashcroft, MSc, Wiebke Appel, MD, Prof Fabrice Barlesi, PhD, Adityanarayan Bhatnagar, MD, Andrea Bezjak, MD, Felipe Cardenal, PhD, Prof Pierre Fournel, MD, Susan Harden, DM [Oxon], Cecile Le Pechoux, MD, Rhona McMenemin, MSc, Nazia Mohammed, FRCR, Mary O'Brien, MD, Jason Pantarotto, MD, Prof Veerle Surmont, PhD, Prof Jan P Van Meerbeeck, PhD, Prof Penella J Woll, FRCP, Prof Paul Lorigan, FRCP, Prof Fiona Blackhall, PhD The Lancet Oncology Volume 18, Issue 8, Pages 1116-1125 (August 2017) DOI: 10.1016/S1470-2045(17)30318-2 Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license Terms and Conditions

Figure 1 Trial profile *One patient withdrew consent for twice-daily radiotherapy. †Dose constraints to organs at risk not met in four patients and twice-daily radiotherapy given in error to two patients. ‡Six patients did not receive any chemotherapy and two patients died during cycle one before toxicity assessment. ¶Seven patients did not receive any chemotherapy and three patients died during cycle one before toxicity assessment. Numbers assessed and ineligible are unavailable because screening logs were not completed by all centres. The Lancet Oncology 2017 18, 1116-1125DOI: (10.1016/S1470-2045(17)30318-2) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license Terms and Conditions

Figure 2 Overall and progression-free survival (A) Overall survival. (B) Local progression-free survival. (C) Metastatic progression-free survival. HR=hazard ratio. The Lancet Oncology 2017 18, 1116-1125DOI: (10.1016/S1470-2045(17)30318-2) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license Terms and Conditions